Skip to search formSkip to main contentSkip to account menu

onartuzumab

Known as: Anti-MET Monoclonal Antibody MetMAb, MetMAb 
A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

OA-5D5

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
BACKGROUND The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic… 
Highly Cited
2015
Highly Cited
2015
METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).
4012 Background: Dysregulation of the MET/HGF pathway is associated with poor prognosis in GEC. Onartuzumab (O), a monovalent… 
Highly Cited
2015
Highly Cited
2015
Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
2013
2013
MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or…
TPS4155 Background: Dysregulation of the HGF/MET pathway in patients with gastroesophageal cancer (GEC) is associated with… 
Review
2013
Review
2013
Which are the antibodies to watch in 2013?
The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in… 
2013
2013
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors
Onartuzumab is a unique, humanized, monovalent (one‐armed) monoclonal antibody (mAb) against the MET receptor. The intravenous… 
Review
2012
Review
2012
Targeting the Met pathway in lung cancer
Dysregulation of Met signaling has been implicated in the initiation, progression and metastasis of human cancers, and therefore… 
Review
2011
Review
2011
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Hepatocyte growth factor receptor (HGFR), the product of the MET gene, plays an important role in normal cellular function and… 
Review
2011
Review
2011
Role of MetMAb (OA-5D5) in c-MET active lung malignancies
Introduction: MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase… 
Review
2010
Review
2010
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Products of proto-oncogenes c-MET and RON belong to a subfamily of receptor tyrosine kinases that contribute significantly to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)